Med. praxi. 2025;22(1):66-70 | DOI: 10.36290/med.2025.008
HIV pre‑exposure prophylaxis (PrEP)
- Infekční oddělení a HIV centrum, Masarykova nemocnice v Ústí nad Labem, Krajská zdravotní, a. s.
Thanks to modern treatment, HIV infection is now seen as a chronic disease with a survival rate comparable to the general population. Early diagnosis and the use of antiviral drugs, which stop the virus from multiplying and making the patient infectious (treatment as prevention), is essential. Another way to prevent HIV/AIDS is pre-exposure prophylaxis (PrEP), which is when HIV-negative people who are at high risk of infection take antiviral drugs. This review article talks about the clinical trials, the right drugs, how they are used (daily, on-demand and injectable), counselling and testing needed to make this a safe and effective way to prevent HIV.
Keywords: pre‑exposure prophylaxis, HIV, AIDS, tenofovir, emtricitabine, cabotegravir.
Received: January 13, 2025; Revised: February 4, 2025; Accepted: February 4, 2025; Published: February 20, 2025 Show citation
References
- UNAIDS. 2025 AIDS Targets. Available from: https://www.unaids.org/sites/default/files/2025-AIDS‑Targets_en.pdf.
- SZÚ. Celkový stav vyšetřování HIV protilátek v České republice. Kumulativní údaje ke dni 31. 12. 2024. https://szu.gov.cz/wp‑content/uploads/2025/02/HIV_AIDS_12_2024.pdf.
- Grant RM, Lama JR, Anderson PL, et al. Preexposure Chemoprophylaxis for HIV Prevention in Men Who Have Sex with Men. N Engl J Med. 2010;363:2587-2599. DOI: 10.1056/NEJMoa1011205.
Go to original source... 
Go to PubMed... - Baeten JM, Donell D, Ndase P, et al. Antiretroviral Prophylaxis for HIV Prevention in Heterosexual Men and Women. N Engl J Med. 2012;367:399-410. DOI: 10.1056/NEJMoa1108524. Go to original source... Go to PubMed...
- Molina JM, Capitant C, Spire B, et al. On‑Demand Preexposure Prophylaxis in Men at High Risk for HIV-1 Infection. N Engl J Med. 2015;373:2237-2246. DOI: 10.1056/NEJMoa1506273. Go to original source... Go to PubMed...
- McCormack S, Dunn DT, Desai M, et al. Pre‑exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open‑label randomised trial. Lancet. 2016;387(10013):53-60. doi.org/10.1016/S0140-6736(15)00056-2. Go to original source... Go to PubMed...
- Landovitz RJ, Donell D, Clement ME, et al. Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women. N Engl J Med. 2021;385:595-608. DOI: 10.1056/NEJMoa2101016. Go to original source... Go to PubMed...
- Delany‑Moretlwe S, Hughes JP, Bock P, et al. Cabotegravir for the prevention of HIV-1 in women: results from HPTN 084, a phase 3, randomised clinical trial. Lancet. 2022;399(10337):1779-1789. doi.org/10.1016/S0140-6736(22)00538-4.
- Dlouhý P, Zlámal M, Bartovská Z, et al. Preexpoziční profylaxe HIV (PrEP) a postexpoziční profylaxe HIV (PEP). Doporučený postup Společnosti infekčního lékařství ČLS JEP. Available from: https://infektologie.cz/standardy2/DP_PrEP_PEP_24.pdf.